Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/3660
Title: | Vitamin D Endocrine System and COVID-19 |
Authors: | Bouillon, Roger Quesada-Gomez, José Manuel |
metadata.dc.contributor.authoraffiliation: | [Bouillon,R] Laboratory of Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium. [Quesada-Gomez,JM] Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Fundación Progreso y Salud, Córdoba, Spain. [Quesada-Gomez,JM] CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. |
Keywords: | Vitamin D;Calcifediol;COVID-19;Mortality;Acute respiratory distress syndrome;Intensive care treatment;Vitamina D;Mortalidad;Síndrome de dificultad respiratoria |
metadata.dc.subject.mesh: | Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Cholestanes::Cholestenes::Cholecalciferol::Hydroxycholecalciferols::Calcifediol Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Secosteroids::Vitamin D Medical Subject Headings::Technology and Food and Beverages::Food and Beverages::Food::Dietary Supplements Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Critical Care Medical Subject Headings::Anatomy::Endocrine System Medical Subject Headings::Diseases::Respiratory Tract Diseases::Lung Diseases::Respiratory Distress Syndrome, Adult Medical Subject Headings::Anatomy::Cardiovascular System Medical Subject Headings::Health Care::Health Services Administration::Patient Care Management::Delivery of Health Care Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections Medical Subject Headings::Organisms::Viruses::RNA Viruses::Nidovirales::Coronaviridae::Coronavirus::SARS Virus |
Issue Date: | Dec-2021 |
Publisher: | Wiley-Blackwell Publishing |
Citation: | Bouillon R, Quesada-Gomez JM. Vitamin D Endocrine System and COVID-19. JBMR Plus. 2021 Nov 17;5(12):e10576. |
Abstract: | Preclinical data strongly suggest that the vitamin D endocrine system (VDES) may have extraskeletal effects. Cells of the immune and cardiovascular systems and lungs can express the vitamin D receptor, and overall these cells respond in a coherent fashion when exposed to 1,25-dihydroxyvitamin D, the main metabolite of the VDES. Supplementation of vitamin D-deficient subjects may decrease the risk of upper respiratory infections. The VDES also has broad anti-inflammatory and anti-thrombotic effects, and other mechanisms argue for a potential beneficial effect of a good vitamin D status on acute respiratory distress syndrome, a major complication of this SARS-2/COVID-19 infection. Activation of the VDES may thus have beneficial effects on the severity of COVID-19. Meta-analysis of observational data show that a better vitamin D status decreased the requirement of intensive care treatment or decreased mortality. A pilot study in Cordoba indicated that admission to intensive care was drastically reduced by administration of a high dose of calcifediol early after hospital admission for COVID-19. A large observational study in Barcelona confirmed that such therapy significantly decreased the odds ratio (OR) of mortality (OR = 0.52). This was also the conclusion of a retrospective study in five hospitals of Southern Spain. A retrospective study on all Andalusian patients hospitalized because of COVID-19, based on real-world data from the health care system, concluded that prescription of calcifediol (hazard ratio [HR] = 0.67) or vitamin D (HR = 0.75), 15 days before hospital admission decreased mortality within the first month. In conclusion, a good vitamin D status may have beneficial effects on the course of COVID-19. This needs to be confirmed by large, randomized trials, but in the meantime, we recommend (rapid) correction of 25 hydroxyvitamin D (25OHD) deficiency in subjects exposed to this coronavirus. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. |
URI: | http://hdl.handle.net/10668/3660 |
metadata.dc.relation.publisherversion: | https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbm4.10576 |
metadata.dc.identifier.doi: | 10.1002/jbm4.10576 |
ISSN: | 2473-4039 (Online) |
Appears in Collections: | 01- Artículos - Hospital Reina Sofía 01- Artículos - IMIBIC. Instituto Maimónides de Investigación Biomédica de Córdoba |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Bouillon_VitaminDEndocrine.pdf | Artículo original | 1,03 MB | Adobe PDF | View/Open |
This item is protected by original copyright |
This item is licensed under a Creative Commons License